

Francesca Carubbi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1199193/publications.pdf>

Version: 2024-02-01

49
papers

1,316
citations

304602

22
h-index

345118

36
g-index

51
all docs

51
docs citations

51
times ranked

1952
citing authors

#	ARTICLE	IF	CITATIONS
1	Trabecular complexity as an early marker of cardiac involvement in Fabry disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 200-208.	0.5	5
2	Nutrition in adult patients with selected lysosomal storage diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 733-744.	1.1	7
3	The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease. <i>Liver International</i> , 2021, 41, 224-225.	1.9	1
4	A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2021, .	0.7	2
5	Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Peripheral Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4466.	1.0	4
6	Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives?. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 262.	1.2	3
7	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. <i>Liver International</i> , 2020, 40, 3061-3070.	1.9	13
8	Hyperferritinemia and diagnosis of type 1 Gaucher disease. <i>American Journal of Hematology</i> , 2020, 95, 570-576.	2.0	6
9	Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. <i>Digestive and Liver Disease</i> , 2020, 52, 368-373.	0.4	15
10	Gaucher Disease in Bone: From Pathophysiology to Practice. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 996-1013.	3.1	94
11	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. <i>Atherosclerosis</i> , 2019, 284, 66-74.	0.4	58
12	The association of Mediterranean diet and exercise modifications with anthropometric parameters in a psychiatric community population: A pilot study. <i>Preventive Medicine Reports</i> , 2018, 9, 68-71.	0.8	3
13	Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 74-80.	0.6	26
14	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.4	48
15	Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 64-72.	0.5	18
16	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
17	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
18	Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice. <i>Advances in Therapy</i> , 2014, 31, 1197-1212.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014, 232, 99-109.	0.4	113
20	Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study. <i>Journal of Inherited Metabolic Disease</i> , 2013, 36, 83-89.	1.7	29
21	Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 353-358.	0.7	35
22	Minimal disease activity in Gaucher disease: Criteria for definition. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 521-525.	0.5	4
23	Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2012, 44, 1018-1026.	0.4	18
24	Fabry disease: raising awareness of the disease among physicians. <i>Internal and Emergency Medicine</i> , 2012, 7, 227-231.	1.0	8
25	New motor outcome function measures in evaluation of Late Onset Pompe disease before and after enzyme replacement therapy. <i>Muscle and Nerve</i> , 2012, 45, 831-834.	1.0	56
26	Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. <i>Journal of Neurology</i> , 2012, 259, 952-958.	1.8	117
27	Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A5 deficiency due to a novel mutation in the <i>APOA5</i> gene. <i>Journal of Internal Medicine</i> , 2008, 263, 450-458.	2.7	50
28	A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. <i>Haematologica</i> , 2008, 93, 1211-1218.	1.7	55
29	Nonalcoholic Fatty Liver Disease Induced by Leuprorelin Acetate. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 107-110.	1.1	16
30	W15-P-001 Role of nuclear receptors in the molecular regulation of cholesterol homeostasis in cultured human hepatocytes. <i>Atherosclerosis Supplements</i> , 2005, 6, 96-97.	1.2	0
31	Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2002, 1580, 31-39.	1.2	15
32	Suppression of bile acid synthesis, but not of hepatic cholesterol 7 α -hydroxylase expression, by obstructive cholestasis in humans. <i>Hepatology</i> , 2001, 34, 234-242.	3.6	31
33	Review article: effect of bile salt pool composition on hepatic and biliary functions. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 14-18.	1.9	30
34	Extent of bile acid-induced hepatic damage dictates activin a secretion in HepG2 cells. <i>Journal of Hepatology</i> , 2000, 32, 77.	1.8	0
35	Herpesvirus DNA is frequently detected in liver tissue from hepatitis C patients. <i>Journal of Clinical Virology</i> , 1999, 14, 9-16.	1.6	2
36	Effect of liver cirrhosis on the systemic availability of naltrexone in humans. <i>Journal of Hepatology</i> , 1997, 27, 505-511.	1.8	40

#	ARTICLE	IF	CITATIONS
37	Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans. <i>Hepatology</i> , 1997, 25, 1306-1314.	3.6	21
38	Growth of human herpesvirus 6 in HEPG2 cells. <i>Virus Research</i> , 1996, 45, 75-85.	1.1	33
39	Prevalence rates of gallstone disease in Italy. <i>European Journal of Epidemiology</i> , 1994, 10, 143-150.	2.5	45
40	Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. <i>Hepatology</i> , 1994, 19, 882-888.	3.6	30
41	Effect of diabetic autonomic neuropathy on gall bladder kinetics in insulin-dependent diabetic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 765-772.	0.8	2
42	High molecular weight biliary protein concentration increases selectively after hydrophobic bile acids (BA) administration. <i>Hepatology</i> , 1993, 18, A304.	3.6	1
43	Effect of taurohyodeoxycholic acid on biliary lipid secretion in man. <i>Hepatology</i> , 1993, 18, A308.	3.6	1
44	Hepatotoxic and hepatoprotective effects of bile salts (BS) depend on their physico-chemical properties. <i>Hepatology</i> , 1993, 18, A313.	3.6	1
45	Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. <i>Biochemical and Biophysical Research Communications</i> , 1992, 183, 1203-1208.	1.0	30
46	Regulation of bile acid synthesis in humans: Effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7α -hydroxylation rates in vivo. <i>Hepatology</i> , 1991, 14, 830-837.	3.6	61
47	Assay of HMG-CoA reductase activity in the evaluation of cholesterol synthesis in man. <i>Clinica Chimica Acta</i> , 1989, 183, 77-81.	0.5	8
48	Effect of small doses of deoxycholic acid on bile cholesterol saturation in patients with liver cirrhosis. <i>Gut</i> , 1986, 27, 23-28.	6.1	9
49	Cholesterol esterase activity of human intestinal mucosa. <i>Digestive Diseases and Sciences</i> , 1985, 30, 1053-1064.	1.1	5